Lancet
-
Randomized Controlled Trial Multicenter Study
Non-invasive ventilation after extubation in hypercapnic patients with chronic respiratory disorders: randomised controlled trial.
Non-invasive ventilation can prevent respiratory failure after extubation in individuals at increased risk of this complication, and enhanced survival in patients with hypercapnia has been recorded. We aimed to assess prospectively the effectiveness of non-invasive ventilation after extubation in patients with hypercapnia and as rescue therapy when respiratory failure develops. ⋯ IDIBAPS, CibeRes, Fondo de Investigaciones Sanitarias, European Respiratory Society.
-
Randomized Controlled Trial Multicenter Study Comparative Study
Surgery versus non-surgical therapy for carpal tunnel syndrome: a randomised parallel-group trial.
A previous randomised controlled trial reported greater efficacy of surgery than of splinting for patients with carpal tunnel syndrome. Our aim was to compare surgical versus multi-modality, non-surgical treatment for patients with carpal tunnel syndrome without denervation. We hypothesised that surgery would result in improved functional and symptom outcomes. ⋯ NIH/NIAMS 5P60AR048093 and the Intramural Research Program of the NIH Clinical Center.
-
Randomized Controlled Trial Multicenter Study Comparative Study
Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial.
Robust evidence to direct management of pregnant women with mild hypertensive disease at term is scarce. We investigated whether induction of labour in women with a singleton pregnancy complicated by gestational hypertension or mild pre-eclampsia reduces severe maternal morbidity. ⋯ ZonMw.
-
Randomized Controlled Trial Multicenter Study Comparative Study
Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial.
Otamixaban is an intravenous direct factor Xa inhibitor. We aimed to assess its efficacy and safety in non-ST-elevation acute coronary syndromes and to identify the optimum dose range for further assessment in a phase 3 study. ⋯ Sanofi-Aventis.